SCHEMBL5363038

SCHEMBL5363038

Cn1cc(Cl)c(C=C2C(=O)Nc3ccc(S(=O)(=O)Nc4ccc(C(F)(F)F)cc4)cc32)n1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MOGAT2 Q3SYC2 6/20 0.52
MGAT2 Q10469 5/20 0.51
MGAT1 P26572 2/20 0.41
MGAT3 Q09327 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
TLK2 Q86UE8 2/20 0.40
MEN1 O00255 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 1/20 0.40
PRKDC P78527 1/20 0.40
SYK P43405 2/20 0.39
PDPK1 O15530 1/20 0.39
NTRK1 P04629 1/20 0.39
FCER2 P06734 1/20 0.39
NTRK3 Q16288 1/20 0.39
NTRK2 Q16620 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359158 0.84 SYK (0.53) SYKNTRK1FCER2NTRK3NTRK2
SCHEMBL5358368 0.81 MOGAT2 (0.61) MOGAT2MGAT2TLK2MEN1ALOX15
SCHEMBL7138855 0.81 MOGAT2 (0.55) MOGAT2MGAT2
SCHEMBL5368255 0.80 MOGAT2 (0.55) MOGAT2MGAT2MEN1ALOX15MAPK1
SCHEMBL7138959 0.80 MOGAT2 (0.54) MOGAT2MGAT2MGAT1MGAT3
SCHEMBL5362279 0.79 MOGAT2 (0.57) MOGAT2MGAT2TLK2MEN1ALOX15
SCHEMBL5368431 0.79 MOGAT2 (0.55) MOGAT2MGAT2MEN1ALOX15MAPK1
SCHEMBL5370558 0.79 MOGAT2 (0.53) MOGAT2MGAT2TLK2MEN1KMT2A
SCHEMBL5361553 0.79 MOGAT2 (0.57) MOGAT2MGAT2TLK2MEN1ALOX15
SCHEMBL5366196 0.79 MOGAT2 (0.51) MOGAT2MGAT2TLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MOGAT2 1159/4885MGAT2 4714/4885MGAT1 4468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.